GSK plc Announces New Directorship for Dr. Hal Barron

This report details the appointment of Dr. Hal Barron, a Non-Executive Director at GSK plc, as an Independent Director and Chair of the Nominating and Corporate Governance Committee of Quantinuum Inc. This appointment, effective June 4, 2026, was made in accordance with UK Listing Rule 6.4.9R(2). The filing was issued by GSK plc on June 9, 2026, from London, UK. GSK plc is a global biopharma company focused on uniting science, technology, and talent to prevent disease. The company is registered in England & Wales and its principal executive office is located at 79 New Oxford Street, London, WC1A 1DG. The report is signed by Victoria Whyte, Company Secretary and Authorized Signatory for GSK plc.